# A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

> **NCT00631917** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 774 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Aliskiren
- **DRUG:** Ramipril
- **OTHER:** Placebo to Ramipril
- **OTHER:** Placebo to Aliskiren

## Key facts

- **NCT ID:** NCT00631917
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 774 (ACTUAL)
- **Last updated:** 2011-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00631917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00631917, "A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00631917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*